Stockscreener 앱 받기
19.72
7.59%
-1.62
시간 외 거래:
19.72
Sarepta Therapeutics Inc 주식(SRPT)의 최신 뉴스
Did FDA Green Light for ELEVIDYS and Pipeline Progress Just Shift Sarepta Therapeutics' (SRPT) Narrative? - simplywall.st
How Do Sarepta (SRPT)’s Enhanced Safety Moves Reflect Its Approach to Long-Term Risk Management? - Yahoo Finance
Sarepta Therapeutics (SRPT) Gets a Buy from Wells Fargo - The Globe and Mail
Why analysts raise outlook for Sarepta Therapeutics Inc. (AB3A) stockJuly 2025 Action & Entry Point Confirmation Alerts - BỘ NỘI VỤ
Sarepta (SRPT) gets FDA approval on new gene therapy study - Investorsobserver
Sarepta Therapeutics, Inc. (SRPT) Stock Forecasts - Yahoo Finance
Tech Stocks Surge Ahead Of Thanksgiving, Robinhood Rallies 10%: What's Moving Markets Wednesday? - Benzinga
Sarepta cleared to test new safety regimen for Duchenne drug - statnews.com
Sarepta to investigate immunosuppressant Elevidys combo to avoid fatal AEs - Yahoo
Sell Rating for Sarepta Therapeutics Due to Risks in ENDEAVOR Study and Expected Share Price Decline - TipRanks
SRPT INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit (PR Newswire) - Aktiellt
Local Pharmaceutical Company Earns $200 Million Milestone Payment in Sarepta Partnership Pasadena-based Arrowhead Pharmaceuticals Inc., based in Pasadena, announced it has earned a $200 million milestone payment from Sarepta Therapeutics afte - facebook.com
Sarepta to test immunosuppressive Elevidys regimen in non-ambulatory DMD patients - FirstWord Pharma
Sarepta's Elevidys Gets Boxed Warning for ALI and ALF - CGTLive®
Sarepta gets FDA's go-ahead to study immunosuppressive Elevidys regimen in bid to reverse label restriction - Fierce Pharma
Sarepta's Stock Rises on Positive Updates on DM1 Therapy - Yahoo Finance
Sarepta Therapeutics: Hold Rating Amid ENDEAVOR Progress and Short-term Challenges - TipRanks
Sarepta Secures FDA Nod For Elevidys Study To Reduce Liver Injury Risk - Benzinga
Trading the Move, Not the Narrative: (SRPT) Edition - news.stocktradersdaily.com
Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne - Lelezard
Sarepta Wins FDA Approval To Begin Study On Reducing Liver Injury Risk With Elevidys - Stocktwits
Sarepta (SRPT) Advances with FDA Approval for New Dystrophy Treatment Study - GuruFocus
Sarepta Therapeutics Receives FDA Approval for Dosing Levels for Elevidys Study to Treat Duchenne Muscular Dystrophy - MarketScreener
Sarepta receives FDA approval for ELEVIDYS study with enhanced immunosuppression - StreetInsider
SRPTSarepta Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Bernstein raises Sarepta Therapeutics stock price target to $20 on DMD estimates - Investing.com
Local Pharmaceutical Company Earns $200 Million Milestone Payment in Sarepta Partnership - Pasadena Now
Cautious Outlook on Sarepta Therapeutics Amid Early-Stage Trials and Financial Commitments - TipRanks
Sarepta shares positive safety update on DM1 asset as Arrowhead snares $200M milestone - Fierce Biotech
ELEVIDYS Label Changes and Pipeline Progress Could Be a Game Changer for Sarepta Therapeutics (SRPT) - Sahm
Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics - BioSpace
Arrowhead (ARWR) Secures $200M Milestone Payment from Sarepta - GuruFocus
Arrowhead Pharma secures $200M milestone from Sarepta Therapeutics - MSN
Arrowhead Pharmaceuticals to Receive $200 Million Payment From Sarepta Therapeutics for Meeting ARO-DM1 Milestone - MarketScreener
Sarepta advances phase 1/2 study of DM1 treatment, triggers milestone payment By Investing.com - Investing.com South Africa
Sarepta provides progress update for SRP-1003, its treatment for myotonic dystrophy type 1 - MarketScreener
Sarepta advances phase 1/2 study of DM1 treatment, triggers milestone payment - Investing.com
Sarepta advances SRP-1003 trial, triggers $200 million milestone payment - StreetInsider
Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1 - Sarepta Therapeutics
Sarepta terminates Hansa-partnered gene therapy combination trial - Clinical Trials Arena
Tangible book value per share of Sarepta Therapeutics, Inc. – TRADEGATE:AB3A - TradingView
Sarepta Therapeutics (SRPT): Valuation Update Following ELEVIDYS Label Changes and Heightened Safety Warnings - simplywall.st
Is Sarepta Therapeutics Inc. stock overvalued by current metricsGap Down & Low Drawdown Momentum Ideas - newser.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc.SRPT - PR Newswire
In new FDA role, Pazdur will decide the future of Sarepta’s Duchenne drugs - statnews.com
Will Sarepta Therapeutics Inc. (AB3A) stock test record highs in 2025Weekly Gains Summary & Scalable Portfolio Growth Methods - newser.com
Mizuho reaffirms Sarepta Therapeutics stock with Outperform rating - Investing.com
Mizuho reaffirms Sarepta Therapeutics stock with Outperform rating By Investing.com - Investing.com Nigeria
Why Sarepta Therapeutics Inc. (AB3A) stock signals breakout potentialJuly 2025 Action & Verified Swing Trading Watchlist - newser.com
What technical models suggest about Sarepta Therapeutics Inc.’s comeback - newser.com
Sarepta Therapeutics Inc. stock trend forecastJuly 2025 Macro Moves & Smart Allocation Stock Reports - newser.com
[Form 4] Sarepta Therapeutics, Inc. Insider Trading Activity - Stock Titan
Relative strength of Sarepta Therapeutics Inc. in sector analysisJuly 2025 Drop Watch & Growth Focused Stock Reports - newser.com
How Sarepta Therapeutics Inc. (AB3A) stock expands through international markets2025 Key Lessons & Expert Approved Momentum Trade Ideas - newser.com
SAREPTA THERAPEUTICS INC (SRPT.MX) stock major holders - Yahoo Finance UK
Is Sarepta Therapeutics Inc. stock ready for a breakoutMarket Growth Report & Low Volatility Stock Recommendations - newser.com
Using Bollinger Bands to evaluate Sarepta Therapeutics Inc.Rate Hike & Safe Capital Growth Trade Ideas - newser.com
Will Sarepta Therapeutics Inc. (AB3A) stock profit from AI boomRecession Risk & Fast Moving Stock Watchlists - newser.com
Is Sarepta Therapeutics Inc. stock attractive for growth ETFs2025 Market WrapUp & Scalable Portfolio Growth Ideas - newser.com
0.30%
1.75%
자본화:
|
볼륨(24시간):